Medical device company Saluda Medical Pty Limited said on Monday that it has received USD75m under its equity financing with Boston Scientific Corporation (NYSE:BSX) and Redmile Group LLC.
Saluda Medical intends to use the funds for the final stages of development through commercialisation of its Evoke ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System for the treatment of chronic intractable pain of the trunk and limbs.
Boston Scientific, Redmile and one other financial institution participated in the capital raise.
Piper Jaffray acted as financial advisor to Saluda for the equity financing.
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Novocure announces presentation of new TTFields research at EANO and ESMO 2025 meetings
OSR Holdings to acquire Korean non-invasive glucose monitor developer Woori IO
Autonomix Medical secures new US patent to expand precision nerve-targeted therapies
MedHub-AI's AutocathFFR receives national reimbursement approval in Japan
Microbot Medical secures first Japanese patent for Liberty robotic system following FDA clearance
Polarean Imaging signs new supply agreementwith UVA Health for clinical Xenon MRI
Femasys partners with Kebomed to expand FemBloc permanent birth control in France and Benelux
Implantica receives positive FDA feedback on final RefluxStop PMA submission
Tempus secures FDA clearance for RNA-based xR IVD diagnostic device
Shoulder Innovations expands I-Series portfolio with launch of InSet 70 Humeral Stem
GSK commits USD30bn to US R&D and manufacturing expansion
ArtPlayer Promotes Elderly Wellbeing with Digital Signage and Streaming Art in Finnish Care Homes